Lupin takes "more shots at the goal" with $880m US buy
This article was originally published in Scrip
Executive Summary
Lupin has snapped up the privately owned niche firm Gavis Pharmaceuticals LLC and Novel Laboratories for $880m, marking India's largest pharma buyout in the US in recent times.
You may also be interested in...
Profile: Lupin CFO Swaminathan, The ‘Constant Learner'
CFOs are known for talking about their top and bottom lines, but not so much about what makes them tick. Here we give you a peek into the life story of Lupin CFO Ramesh Swaminathan, who shares with Scrip why he made the shift from Henkel in Germany to the Indian firm, M&A learnings, admiration for peer Sun Pharma and his own career ambitions.
Lupin's Metformin US Outlook Stays Sunny; Russian Buy Under Review
Lupin reported a strong set of numbers for the first quarter ended June and expects US sales of its generic version of Glumetza (metformin HCL extended-release tablets) to stay a key contributor despite imminent competition from Sun Pharma, among others. The Indian firm, though, appears to be re-evaluating its Russian acquisition.
Generic Glumetza Scripts Lupin's Strong US Run
Lupin Ltd. has reported stellar numbers for the fourth quarter ended March 2016, buoyed by US sales of its generic version of Glumetza (metformin HCL extended-release tablets), the Valeant Pharmaceuticals International Inc. drug dumped earlier this year by pharmacy benefits manager, Express Scripts Holding Co.